Vutrisiran : Alnylam Pharmaceuticals reveals positive results from HELIOS-B Phase 3 study
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, has unveiled promising results from the HELIOS-B Phase 3 study of vutrisiran, a ... Read More
GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate ... Read More
Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients ... Read More
Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients ... Read More
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis. Their drug, Cyltezo, a biosimilar to AbbVie's ... Read More
SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer
In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee's Pharmaceutical, has announced the ... Read More
Teva and Regeneron report positive Phase 3 results for Fasinumab in osteoarthritis pain management
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced successful outcomes from their phase 3 study of fasinumab, a nerve growth factor (NGF) antibody, in patients ... Read More
Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination ... Read More
AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More
Roche’s Perjeta shows significant promise in phase 3 breast cancer trial
Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy. This ... Read More